论文部分内容阅读
目的探讨多西他赛联合奈达铂对卵巢上皮性癌患者血清CA125及LPA含量的影响。方法将2011年1月至2013年3月在本院接受多西他赛联合奈达铂方案化疗的49例卵巢上皮性癌患者作为研究对象,并以同期在本院进行体检的50例健康女性作为对照,采用放射免疫分析法(IRMA)及酶联免疫吸附试验(ELISA)检测受试者血清中的CA125及LPA的含量。结果化疗前,卵巢上皮性癌患者血清中CA125及LPA含量显著高于对照组(P<0.05);而化疗后,卵巢上皮性癌患者血清中CA125及LPA含量较化疗前显著降低(P<0.05),化疗后卵巢上皮性癌患者血清中CA125及LPA含量与对照组比较均无统计学差异(P>0.05)。多西他赛联合奈达铂方案治疗卵巢上皮性癌的有效率为95.92%,且疗效与患者血清CA125及LPA水平显著相关,治疗效果越好,血清CA125及LPA水平越低。结论多西他赛联合奈达铂方案治疗卵巢上皮性癌患者的效果较好,可能与影响患者血清CA125及LPA的水平有关。
Objective To investigate the effect of docetaxel combined with nedaplatin on serum CA125 and LPA in patients with epithelial ovarian cancer. Methods A total of 49 patients with epithelial ovarian cancer who underwent docetaxel and nedaplatin regimen in our hospital from January 2011 to March 2013 were enrolled in this study. Fifty healthy women As a control, the contents of CA125 and LPA in serum of the subjects were detected by radioimmunoassay (IRMA) and enzyme-linked immunosorbent assay (ELISA). Results Before chemotherapy, the levels of serum CA125 and LPA in patients with epithelial ovarian cancer were significantly higher than those in the control group (P <0.05). After chemotherapy, the levels of serum CA125 and LPA in patients with epithelial ovarian cancer were significantly lower than those before chemotherapy (P <0.05 ), The levels of CA125 and LPA in the serum of patients with epithelial ovarian cancer after chemotherapy were not significantly different from those in the control group (P> 0.05). Docetaxel combined with nedaplatin regimen for the treatment of epithelial ovarian cancer was 95.92%, and the efficacy of patients with serum CA125 and LPA levels were significantly correlated, the better the treatment, the lower serum CA125 and LPA levels. Conclusion Docetaxel combined with nedaplatin regimen in patients with epithelial ovarian cancer treatment is better, and may affect the level of serum CA125 and LPA.